1. Search Result
Search Result
Results for "

Respiratory syncytial virus

" in MedChemExpress (MCE) Product Catalog:

89

Inhibitors & Agonists

2

Peptides

18

Inhibitory Antibodies

10

Natural
Products

10

Recombinant Proteins

3

Isotope-Labeled Compounds

3

Oligonucleotides

Targets Recommended:
Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-104032
    Ac-CoA Synthase-IN-1
    5+ Cited Publications

    RSV Infection Metabolic Disease
    Ac-CoA Synthase-IN-1 is a potent, reversible acetate-dependent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC50 of 0.6 μM . Ac-CoA Synthase-IN-1 inhibits the respiratory syncytial virus (RSV) .
    Ac-CoA Synthase-IN-1
  • HY-N6771
    Cyclopiazonic acid
    5+ Cited Publications

    Calcium Channel 5-HT Receptor MDM-2/p53 Apoptosis RSV Infection
    Cyclopiazonic acid is an endoplasmic reticulum calcium ATPase (ECAs) inhibitor and human respiratory syncytial virus (RSV) inhibitor (EC50 value of 4.13 μ M), which can reduce the antagonistic effect of 5-HT receptors in rat thoracic aorta, induce p53 dependent cell apoptosis and reproductive toxicity in mouse testes, and inhibit the biological activation of aflatoxin B [1][4][5].
    Cyclopiazonic acid
  • HY-P9944
    Palivizumab
    3 Publications Verification

    MEDI 493

    RSV Infection Inflammation/Immunology Cancer
    Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
    Palivizumab
  • HY-P99756
    Nirsevimab
    2 Publications Verification

    MEDI8897

    RSV Infection
    Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
    Nirsevimab
  • HY-12283
    Rostafuroxin
    2 Publications Verification

    PST 2238

    Na+/K+ ATPase RSV Cardiovascular Disease
    Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na +,K +-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity .
    Rostafuroxin
  • HY-109142
    Ziresovir
    5 Publications Verification

    AK0529; RO-0529

    RSV Infection
    Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species .
    Ziresovir
  • HY-109035
    Inarigivir soproxil
    1 Publications Verification

    SB9200; GS-9992

    HCV HBV Infection
    Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV .
    Inarigivir soproxil
  • HY-145119AS

    VV116; GS-621763-d1 hydrobromide

    SARS-CoV RSV Influenza Virus Infection
    Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .
    Mindeudesivir hydrobromide
  • HY-P99804
    Clesrovimab
    3 Publications Verification

    MK1654

    RSV Infection
    Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding KD values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection .
    Clesrovimab
  • HY-P99209

    MEDI-524

    RSV Infection
    Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
    Motavizumab
  • HY-15970
    Verdinexor
    2 Publications Verification

    KPT-335

    CRM1 Apoptosis RSV Infection Inflammation/Immunology Cancer
    Verdinexor (KPT-335) is an orally active inhibitor for selective inhibitor of nuclear export (SINE). Verdinexor inhibits the respiratory syncytial virus A2 (RSV A2) replication with an IC50 of 0.96 µM. Verdinexor inhibits the function of nuclear export protein Exportin 1 (XPO1/CRM1), inhibiting pro-inflammatory responses. Verdinexor exhibits antitumor effciency .
    Verdinexor
  • HY-12993
    RSV604
    2 Publications Verification

    A-60444

    RSV Infection
    RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a Kd of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC50s=0.8 μM) .
    RSV604
  • HY-150217
    CpG ODN 10101
    2 Publications Verification

    ODN 10101

    Toll-like Receptor (TLR) Infection Inflammation/Immunology
    CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .
    CpG ODN 10101
  • HY-112180
    Rilematovir
    5 Publications Verification

    JNJ-678; JNJ-53718678

    RSV Infection
    Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.
    Rilematovir
  • HY-123475A
    Sisunatovir hydrochloride
    4 Publications Verification

    RV521 hydrochloride

    RSV Infection
    Sisunatovir (RV521) hydrochloride is a potent and orally active respiratory syncytial virus (RSV) inhibitor with IC50 values of 1.4, 1.0 nM for RSV A, RSV B, respectively. Sisunatovir hydrochloride inhibits RSV infection and reduces virus titers in the lungs of mice .
    Sisunatovir hydrochloride
  • HY-123475
    Sisunatovir
    4 Publications Verification

    RV521

    RSV Infection
    Sisunatovir (RV521) is a potent and orally active respiratory syncytial virus (RSV) inhibitor with IC50 values of 1.4, 1.0 nM for RSV A, RSV B, respectively. Sisunatovir inhibits RSV infection and reduces virus titers in the lungs of mice .
    Sisunatovir
  • HY-12983
    ALS-8112
    3 Publications Verification

    RSV Infection
    ALS-8112 is a potent and selective respiratory syncytial virus (RSV) polymerase inhibitor. The 5'-triphosphate form of ALS-8112 inhibits RSV polymerase with an IC50 of 0.02 μM.
    ALS-8112
  • HY-102038
    PC786
    2 Publications Verification

    RSV Infection
    PC786 is an inhaled respiratory syncytial virus (RSV) L protein polymerase inhibitor. PC786 demonstrates potent antiviral activity against RSV-A (IC50 <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM) .
    PC786
  • HY-149648

    RSV DNA/RNA Synthesis Infection
    JNJ-8003 is a potent and orally active non-nucleoside RSV polymerase inhibitor with an IC50 of 0.29 nM. JNJ-8003 targets the L protein polymerase complex of RSV (IC50 = 0.67 nM), and blocks the transcription and replication of the viral genome by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). JNJ-8003 displays subnanomolar activity in vitro as well as prominent efficacy in mice and a neonatal lamb models. JNJ-8003 can be used for the study of respiratory syncytial virus (RSV) .
    JNJ-8003
  • HY-122587

    DNA/RNA Synthesis RSV Infection
    AVG-233 is a potent, orally active RNA dependent RNA polymerase (RdRp) inhibitor. AVG-233 prevents initiation of the viral polymerase complex at the promoter. AVG-233 binding site is present in the L1-1749 fragment. AVG-233 has nanomolar activity against both RSV strains and clinical RSV isolates (EC50=0.14-0.31 μM). AVG-233 can be used for research of respiratory syncytial virus (RSV) .
    AVG-233
  • HY-11097
    TMC353121
    Maximum Cited Publications
    8 Publications Verification

    RSV Infection
    TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC50 of 9.9.
    TMC353121
  • HY-W013605A
    4-Methoxycinnamaldehyde
    2 Publications Verification

    p-Methoxycinnamaldehyde

    Environmental Pollutants RSV Infection
    4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde), an active constituent of Agastache rugosa, exhibits cytoprotective activity against respiratory syncytial virus (RSV) in human larynx carcinoma cell line. 4-Methoxycinnamaldehyde effectively inhibits cytopathic effect of RSV with an estimated IC50 of 0.055 μg/mL .
    4-Methoxycinnamaldehyde
  • HY-W013403

    IFNAR Infection
    2'-Deoxy-2'-fluorouridine is a derivative of the pyrimidine nucleoside uridine. 2'-Deoxy-2'-fluorouridine is a nucleoside analog that inhibits the replication of wild-type viruses by binding to the viral RNA. Hepatitis C polyU/UC RNA strands containing 2'-Deoxy-2'-fluorouridine, bind to RIG-I but do not activate RIG-I signaling in a reporter assay using Huh7 cells. 2'-Deoxy-2'-fluorouridine also has been used as a starting material in the synthesis of respiratory syncytial virus (RSV) polymerase inhibitors. 2'-Deoxy-2'-fluorouridine can incorporate into DNA and RNA in rat and woodchuck model upon administration. 2'-Deoxy-2'-fluorouridine can be studied in anti-viral research .
    2'-Deoxy-2'-fluorouridine
  • HY-P991492

    RSV Infection
    RSM-01 is a monoclonal antibody targeting site Ø of the pre-fusion F glycoprotein (Fusion glycoprotein F0) of respiratory syncytial virus (RSV). RSM-01 can be used in studies related to RSV infection .
    RSM-01
  • HY-12983A
    Lumicitabine
    1 Publications Verification

    ALS-008176; ALS-8176

    RSV Infection
    Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.
    Lumicitabine
  • HY-14460

    FLAP Inflammation/Immunology
    AM679 is a potent, selective 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 2 nM in a human FLAP membrane binding assay. AM679 markedly reduces the respiratory syncytial virus-driven ocular pathology as well as the synthesis of cysteinyl leukotrienes (CysLTs) in the eye .
    AM679
  • HY-120632

    RSV Infection
    BMS-433771 is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 can be used for the research of respiratory tract disease .
    BMS-433771
  • HY-158824A

    ALN-RSV01 sodium

    Small Interfering RNA (siRNA) RSV Infection
    Asvasiran sodium is a siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication.
    Asvasiran sodium
  • HY-P1837

    Influenza Virus HSV Infection
    Influenza HA (518-526) is an H-2d-restricted CTL epitope derived from influenza virus hemagglutinin. Influenza HA (518-526) is highly conserved across various H5N1, some H9N2, and H1N1 strains. Influenza HA (518-526) binds to the mouse MHC class I allele K d to form a complex, which is then recognized by specific CD8 + T cells. Influenza HA (518-526) is an immunodominant epitope in influenza-infected BALB/c mice, and it stimulates CD8 + T cells to secrete IFN-γ to induce a robust immune response. Currently, Influenza HA (518-526) is widely used in research related to respiratory syncytial virus (RSV), influenza virus, and H5N1 influenza .
    Influenza HA (518-526)
  • HY-109004

    BTA-C585

    RSV Infection
    Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection .
    Enzaplatovir
  • HY-12994

    MDT-637

    RSV Infection
    MDT-637 (VP 14637) is a novel respiratory syncytial virus (RSV) fusion inhibitor with an IC50 of 1.42 ng/mL.
    VP-14637
  • HY-143494

    RSV Influenza Virus Infection
    RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage .
    RSV/IAV-IN-3
  • HY-N8448

    Macroantoin F

    RSV Infection
    3,4-Di-O-caffeoyl quinic acid methyl ester (Macroantoin F) is a dicaffeoyl derivative isolated from the rhizome of Elephantopus scaber Linn. 3,4-Di-O-caffeoyl quinic acid methyl ester exhibited in vitro antiviral activity against respiratory syncytial virus (RSV) with an IC50 value of 0.78 μg/mL .
    3,4-Di-O-caffeoyl quinic acid methyl ester
  • HY-115574

    RSV Infection
    RSV L-protein-IN-1 (compound D) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.021 μM). RSV L-protein-IN-1 inhibits Polymerase (IC50=0.089 μM),and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM,HEp-2),also exhibits activity and lowers virus titers in mouse models of RSV infection .
    RSV L-protein-IN-1
  • HY-12993B

    A-60444 (R enantiomer)

    RSV Infection
    RSV604 R enantiomer is the R-enantiomer of RSV604. RSV604 is an inhibitor of respiratory syncytial virus (RSV) replication. R-enantiomer is less active against RSV.
    RSV604 (R enantiomer)
  • HY-111296

    RSV Infection
    YM 53403 is an anti-respiratory syncytial virus (RSV) agent, with an EC50 of 0.20 μM. YM 53403 potently inhibits the replication of RSV strains belonging to both A and B subgroups .
    YM 53403
  • HY-19874

    RSV Infection
    RFI-641 is a selective inhibitor of the respiratory syncytial virus (RSV), with an IC50 of 50 nM. RFI-641 inhibit binding and fusion of enveloped virus via interaction with the viral fusion protein .
    RFI-641
  • HY-P991690

    RSV Infection
    Glarivibart is a humanized IgG1κ monoclonal antibody inhibitor targeting Respiratory syncytial virus (RSV) fusion F protein (RSV-F). Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .
    Glarivibart
  • HY-P991497

    RSV Infection
    ASN-500 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. ASN-500 can be used in respiratory syncytial virus infection research .
    ASN-500
  • HY-126033

    HBV RSV Infection
    Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratory syncytial virus (RSV) with an IC50 of 10.4 μg/mL .
    Sophoranol
  • HY-P991496

    RSV Infection
    IDB-002 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. IDB-002 can be used in respiratory syncytial virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    IDB-002
  • HY-170395

    RSV DNA/RNA Synthesis Infection
    GHP-88309 is a broad-spectrum, orally active antiviral agent targeting paramyxoviruses, that targets the viral polymerase, interupts the viral RNA synthesis, and inhibits respiratory syncytial virus (RSV), measles virus (MeV), and canine distemper virus (CDV) with EC50 of 0.06-1.2 μM. GHP-88309 exhibits anti-infectious efficacy in mouse models .
    GHP-88309
  • HY-11098

    R170591

    RSV Infection
    JNJ 2408068 is a potent RSV (respiratory syncytial virus) inhibitor. JNJ 2408068 significantly inhibits replication of RSV A and B subtypes in the lungs of cotton rats without any evidence of toxicity. The minimum protective dose of JNJ 2408068 appears to be approximately 0.39 mg/kg .
    JNJ 2408068
  • HY-158824

    ALN-RSV01

    Small Interfering RNA (siRNA) RSV Infection
    Asvasiran is a siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication.
    Asvasiran
  • HY-108002

    RSV Infection
    A 33903 is a respiratory syncytial virus (RSV) replication inhibitor. A 33903 can be used for the research of RSV-infection .
    A 33903
  • HY-P991157

    RSV Infection
    Retavibart is a human respiratory syncytial virus (RSV) fusion glycoprotein F. Retavibart can be used for antiviral research. Isotype control: Human IgG1 kappa .
    Retavibart
  • HY-P991500

    RSV Infection
    EVO-46135 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. EVO-46135 can be used in Respiratory syncytial virus infections and Metapneumovirus infections research.
    EVO-46135
  • HY-124052

    RSV Infection
    AZ-27 is a respiratory syncytial virus (RSV) inhibitor. AZ-27 can differentially suppress various RSV polymerase activities at the promoter, thereby inhibiting the early stages of mRNA transcription and genome replication by targeting the promoter .
    AZ-27
  • HY-143495

    RSV Influenza Virus Infection
    RSV-IN-3 (Compound 1) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-3 shows anti-RSV activity (EC50 = 32.70 μM) .
    RSV-IN-3
  • HY-143496

    RSV Influenza Virus Infection
    RSV-IN-4 (Compound 2) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-4 shows anti-RSV activity (EC50 = 11.76 μM) .
    RSV-IN-4

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

 

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

 

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: